Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8461-8470 Newer>

Pharmaceutical Executive November 1, 2012 Jill Wechsler	Budgets, Biosimilars, and Bad Ads While the nation was embroiled in the presidential elections, a number of important legal and regulatory issues absorbed pharmaceutical executives.
Pharmaceutical Executive November 1, 2012 William Looney	Simple Questions for Spain Spain's leading business school, IESE, organized an expert conference to ask how can providers and payers work together to generate more value from existing resources? What must be done to ensure the system continues to create value in the first place?
Chemistry World November 19, 2012	Reckitt steps into Schiff deal Bayer's $1.2 billion bid for Schiff Nutrition, a US company specialising in vitamins and nutritional supplements, could be in trouble following a higher bid from another company.
Chemistry World November 16, 2012 Andrew Turley	What lies within Bayer is looking to 'modestly' increase its R&D budget next year -- it was 3 billion euros( 2.4 billion pounds) for 2012 -- and place new emphasis on transferring ideas between research areas within the company.
Chemistry World November 7, 2012 Andrew Turley	Takeda buys Envoy for $140m The move gives Takeda access to Envoy's 'BacTrap' technology for labeling and extracting the protein-making components of specific types of cells.
Chemistry World November 5, 2012 Andrew Turley	Approval for first gene therapy drug Alipogene tiparvovec, marketed as Glybera, has become the first gene therapy drug to win approval in either the US or the EU.
Chemistry World November 1, 2012 Andrew Turley	Novartis biotech plant for Singapore The new plant, which will make drugs through cell culture, will be located with the Novartis production plant at Tuas.
Chemistry World October 31, 2012 Andrew Turley	Bayer spends $1.2bn on supplement maker German healthcare giant Bayer has struck a deal to buy Schiff Nutrition, a US company specializing in vitamins and nutritional supplements, for $1.2 billion.
Chemistry World October 31, 2012 Derek Lowe	High finance meets big pharma? MIT professor and hedge-fund manager Andrew Lo has a plan to gather together as many plausible early-stage oncology projects as possible, and raise money by 'securitizing' their future revenues and issuing bonds from this portfolio.
Chemistry World October 26, 2012 Andrew Turley	Patent woes lead to sharp sales losses Financial results for the third quarter of 2012 from several big pharma companies reveal a dramatic loss of sales as patent protection for key drugs expires. It is an all too familiar story for the industry
<Older 8461-8470 Newer> Return to current articles.